GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mural Oncology PLC (NAS:MURA) » Definitions » Float Percentage Of Total Shares Outstanding

MURA (Mural Oncology) Float Percentage Of Total Shares Outstanding : 99.64% (As of May. 06, 2025)


View and export this data going back to 2023. Start your Free Trial

What is Mural Oncology Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Mural Oncology's float shares is 17.21 Mil. Mural Oncology's total shares outstanding is 17.27 Mil. Mural Oncology's float percentage of total shares outstanding is 99.64%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Mural Oncology's Insider Ownership is 3.39%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Mural Oncology's Institutional Ownership is 55.11%.

Mural Oncology Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Mural Oncology's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=17.21/17.27
=99.64%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mural Oncology Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mural Oncology PLC (NAS:MURA) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
VRCA MRSN FBRX ITRM IPSC FBLG XLO ATRA ANEB RNTX VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
10 Earlsfort Terrace, Dublin 2, Dublin, IRL, D02 T380
Website
https://www.muraloncology.com
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.